Andrea Morrione
Overview
Explore the profile of Andrea Morrione including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
1912
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Toracchio L, Carrabotta M, Mancarella C, Morrione A, Scotlandi K
Int J Mol Sci
. 2024 Nov;
25(22).
PMID: 39596256
Erythropoietin-producing hepatocellular A2 (EphA2) is a member of the Eph tyrosine kinase receptor family that has been linked to various biological processes. In tumors, EphA2 overexpression is associated with noncanonical...
2.
Andretta E, Costa A, Ventura E, Quintiliani M, Damiano S, Giordano A, et al.
Nutrients
. 2024 Nov;
16(21).
PMID: 39519591
Background/objectives: Mesothelioma is an aggressive cancer with limited treatment options. Mesothelioma therapy often involves a multimodal approach including surgery, radiotherapy and chemotherapy. However, the prognosis for patients remains poor. Difficult...
3.
Tomassetti C, Insinga G, Gimigliano F, Morrione A, Giordano A, Giurisato E
Biomedicines
. 2024 Oct;
12(10).
PMID: 39457693
The colony-stimulating factor 1 receptor (CSF-1R) plays a pivotal role in orchestrating cellular interactions within the tumor microenvironment (TME). Although the CSF-1R has been extensively studied in myeloid cells, the...
4.
Buraschi S, Xu S, Stefanello M, Moskalev I, Morcavallo A, Genua M, et al.
Oncotarget
. 2024 Oct;
15:697-698.
PMID: 39352802
No abstract available.
5.
Costa A, Forte I, Pentimalli F, Iannuzzi C, Alfano L, Capone F, et al.
Front Oncol
. 2024 Jul;
14:1418951.
PMID: 39011477
Introduction: Diffuse pleural mesothelioma (DPM) of the pleura is a highly aggressive and treatment-resistant cancer linked to asbestos exposure. Despite multimodal treatment, the prognosis for DPM patients remains very poor,...
6.
Mancarella C, Morrione A, Scotlandi K
Int J Mol Sci
. 2024 Jun;
25(11).
PMID: 38892104
Dysregulation of the insulin-like growth factor (IGF) system determines the onset of various pathological conditions, including cancer. Accordingly, therapeutic strategies have been developed to block this system in tumor cells,...
7.
Rosati D, Palmieri M, Brunelli G, Morrione A, Iannelli F, Frullanti E, et al.
Comput Struct Biotechnol J
. 2024 Mar;
23:1154-1168.
PMID: 38510977
In recent years, the role of bioinformatics and computational biology together with omics techniques and transcriptomics has gained tremendous importance in biomedicine and healthcare, particularly for the identification of biomarkers...
8.
Canciello A, Benot Dominguez R, Barboni B, Giordano A, Morrione A
Heliyon
. 2024 Mar;
10(6):e27731.
PMID: 38509883
Malignant mesothelioma (MM) is a very aggressive neoplasia with a short life expectancy and limited therapeutic options. Thus, the identification of novel molecular targets is a matter of great urgency....
9.
Cersosimo F, Lonardi S, Ulivieri C, Martini P, Morrione A, Vermi W, et al.
Cancers (Basel)
. 2024 Jan;
16(2).
PMID: 38254773
Colony-stimulating factor 1 receptor (CFS-1R) is a myeloid receptor with a crucial role in monocyte survival and differentiation. Its overexpression is associated with aggressive tumors characterized by an immunosuppressive microenvironment...
10.
Costagliola A, Lombardi R, Liguori G, Morrione A, Giordano A
Cancer Genomics Proteomics
. 2023 Nov;
20(6suppl):637-645.
PMID: 38035703
Prostate cancer (PCa) is the second most common cancer in humans. Peptides have recently been used as targeted therapeutics in cancers, due to their extensive multi-functional applications. Two hypothalamic peptides,...